Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide in HBeAg-Negative Chronic Hepatitis B
NCT03905655Phase 2Completed
- Sponsor
- Romark Laboratories
- Start
- Oct 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitazoxanide in Chronic Hepatitis B (CHB) (4 arms), sponsored by Romark Laboratories. Primary endpoint: Mean Change in Quantitative Hepatitis B Surface Antigen at 12 weeks. Started Oct 2019; status: completed.
02
Drugs
nitazoxanide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03905655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905655.